Olaparib

Generic Name
Olaparib
Brand Names
Lynparza
Drug Type
Small Molecule
Chemical Formula
C24H23FN4O3
CAS Number
763113-22-0
Unique Ingredient Identifier
WOH1JD9AR8
Background

Olaparib is a selective and potent inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, PARP1 and PARP2. PARP inhibitors represent a novel class of anti-cancer therapy and they work by taking advantage of a defect in DNA repair in cancer cells with BRCA mutations and inducing cell death.
...

Indication

Ovarian cancer

Olaparib is indicated for the maintenance treatment of adults with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy.
...

Associated Conditions
Advanced Epithelial Ovarian Cancer, Advanced Fallopian Tube Carcinoma, Advanced Primary Peritoneal Carcinoma, High risk, early breast cancer, Hormone Receptor Positive Breast Carcinoma, Locally Advanced Breast Cancer (LABC), Metastatic Adenocarcinoma of the Pancreas, Metastatic Breast Cancer, Metastatic Castration-Resistant Prostate Cancer (mCRPC), Pancreatic Adenocarcinoma Metastatic, Recurrent Epithelial Ovarian Cancer, Recurrent Fallopian Tube Cancer, Stage I Breast Cancer, Advanced high-grade epithelial ovarian cancer, Advanced, high-grade Primary Peritoneal Cancer, High-grade advanced Fallopian Tubes Cancer, Recurrent platinum sensitive primary peritoneal cancer, Relapsed Platinum-Sensitive Epithelial Ovarian Cancer, Relapsed platinum sensitive primary peritoneal cancer, Relapsed platinum-sensitive fallopian tube cancer
Associated Therapies
Maintenance therapy
Clinical Trials
Related News

Olaparib and Temozolomide in Treating Patients With Relapsed Glioblastoma

Phase 1
Completed
Conditions
Brain and Central Nervous System Tumors
First Posted Date
2011-07-11
Last Posted Date
2018-02-05
Lead Sponsor
Cancer Research UK
Target Recruit Count
34
Registration Number
NCT01390571
Locations
🇬🇧

Bristol Haematology and Oncology Centre, Bristol, England, United Kingdom

🇬🇧

Royal Marsden Hospital, Sutton, England, United Kingdom

🇬🇧

Christie Hospital, Manchester, England, United Kingdom

and more 4 locations

Olaparib in Combination With Carboplatin for Refractory or Recurrent Women s Cancers

First Posted Date
2010-11-09
Last Posted Date
2019-12-17
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
77
Registration Number
NCT01237067
Locations
🇺🇸

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer

First Posted Date
2010-05-05
Last Posted Date
2024-10-31
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
155
Registration Number
NCT01116648
Locations
🇺🇸

National Cancer Institute, Rockville, Maryland, United States

🇺🇸

Massachusetts General Hospital, Charlestown, Massachusetts, United States

🇺🇸

Newton-Wellesley Hospital, Newton, Massachusetts, United States

and more 11 locations

Study to Compare the Efficacy and Safety of Olaparib When Given in Combination With Carboplatin and Paclitaxel, Compared With Carboplatin and Paclitaxel in Patients With Advanced Ovarian Cancer

Phase 2
Active, not recruiting
Conditions
Ovarian Cancer
Interventions
Drug: paclitaxel
Drug: olaparib
Drug: carboplatin
First Posted Date
2010-03-05
Last Posted Date
2024-01-26
Lead Sponsor
AstraZeneca
Target Recruit Count
162
Registration Number
NCT01081951
Locations
🇬🇧

Research Site, Edinburgh, United Kingdom

Open Label Study to Assess Efficacy and Safety of Olaparib in Confirmed Genetic BRCA1 or BRCA2 Mutation Pats

First Posted Date
2010-03-02
Last Posted Date
2024-10-03
Lead Sponsor
AstraZeneca
Target Recruit Count
298
Registration Number
NCT01078662
Locations
🇸🇪

Research Site, Lund, Sweden

Efficacy Study of Olaparib With Paclitaxel Versus Paclitaxel in Gastric Cancer Patients

Phase 2
Completed
Conditions
Gastric Cancer
Interventions
Drug: olaparib
Drug: Placebo
Drug: paclitaxel
First Posted Date
2010-02-05
Last Posted Date
2023-07-20
Lead Sponsor
AstraZeneca
Target Recruit Count
124
Registration Number
NCT01063517
Locations
🇰🇷

Research Site, Taegu, Korea, Republic of

Efficacy and Safety of Olaparib in Pretreated Patients With Measurable Colorectal Cancer, Stratified by Microsatellite Instability (MSI) Status

Phase 2
Completed
Conditions
Colorectal Cancer
Interventions
Drug: olaparib
First Posted Date
2009-06-03
Last Posted Date
2016-11-09
Lead Sponsor
AstraZeneca
Target Recruit Count
33
Registration Number
NCT00912743
Locations
🇺🇸

Research Site, Seattle, Washington, United States

AZD2281 and Irinotecan in Treating Patients With Locally Advanced or Metastatic Colorectal Cancer

Phase 1
Completed
Conditions
Colorectal Cancer
First Posted Date
2007-09-26
Last Posted Date
2023-08-04
Lead Sponsor
NCIC Clinical Trials Group
Target Recruit Count
26
Registration Number
NCT00535353
Locations
🇨🇦

Ottawa Health Research Institute - General Division, Ottawa, Ontario, Canada

🇨🇦

Univ. Health Network-Princess Margaret Hospital, Toronto, Ontario, Canada

Study to Assess The Efficacy and Safety of a PARP Inhibitor For The Treatment of BRCA-positive Advanced Breast Cancer

Phase 2
Completed
Conditions
Breast Neoplasms
Interventions
Drug: Olaparib
First Posted Date
2007-06-29
Last Posted Date
2024-01-19
Lead Sponsor
AstraZeneca
Target Recruit Count
54
Registration Number
NCT00494234
Locations
🇬🇧

Research Site, Manchester, United Kingdom

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy